Table 1 Demographical and clinical data of the DM group and the control group
From: Glycemic control is associated with atrial structural remodeling in patients with type 2 diabetes
Variables | DM group (n = 40) | Control group (n = 46) | t/χ2 | P |
|---|---|---|---|---|
Demographics | ||||
 Age(y) | 61.5 ± 7.8 | 58.8 ± 8.3 | 1.519 | 0.133 |
 Sex(male%) | 25 (62.5%) | 31 (67.4%) | 0.225 | 0.635 |
 BMI(kg/m−2) | 22.1 ± 3.3 | 21.5 ± 3.8 | 0.789 | 0.433 |
Smoking | 11 (27.5%) | 10 (21.7%) | 0.385 | 0.535 |
NYHA functional class | Â | Â | 3.863 | 0.277 |
 I | 5 (12.5%) | 13 (28.3%) |  |  |
 II | 15 (37.5%) | 17 (37.0%) |  |  |
 III | 10 (25.0%) | 9 (19.6%) |  |  |
 IV | 10 (25.0%) | 7 (15.2%) |  |  |
Comorbidities | ||||
 Hypertension | 9 (22.5%) | 17 (37.0%) | 2.120 | 0.145 |
 Atrial fibrillation | 10 (25.0%) | 12 (26.1%) | 0.013 | 0.908 |
 Stroke | 2 (5.0%) | 1 (2.2%) | 0.508 | 0.476 |
 COPD | 3 (7.5%) | 8 (17.4%) | 1.877 | 0.171 |
Laboratory results | ||||
 Hemoglobin (g/dL) | 121.1 ± 23.7 | 112.5 ± 23.2 | 1.699 | 0.093 |
 Creatinine (mg/dL) | 0.725 ± 0.182 | 0.752 ± 0.156 | 0.745 | 0.458 |
 LDL-C (mg/dL) | 137.0 ± 17.5 | 139.0 ± 17.6 | 0.512 | 0.610 |
 FBG (mg/dL) | 193.5 ± 60.6 | 106.7 ± 20.6 | 9.134 | < 0.001 |
 HbA1c (%) | 8.5 ± 2.3 | 5.3 ± 0.9 | 8.559 | < 0.001 |
Drug use | ||||
 Aspirin | 25 (62.5%) | 30 (65.2%) | 0.069 | 0.794 |
 Nitrates | 38 (95.0%) | 40 (87.0%) | 1.641 | 0.200 |
 ACEI/ARB | 5 (12.5%) | 11 (23.9%) | 1.840 | 0.175 |
 Statins | 21 (52.5%) | 18 (39.1%) | 1.543 | 0.214 |
 β-blockers | 12 (30.0%) | 20 (43.5%) | 1.664 | 0.197 |
 Calcium channel blockers | 3 (7.5%) | 6 (13.0%) | 0.702 | 0.402 |